Endologix to Participate at the Guggenheim Securities 4th Annual Boston Healthcare Conference
07 December 2016 - 1:00AM
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative
treatments for aortic disorders, announced today it will
participate at the Guggenheim Securities 4th Annual Boston
Healthcare Conference in Boston, MA. This conference will allow
institutional investors to meet with the Company but does not
include a formal presentation.
|
|
|
|
|
Event: |
|
|
Guggenheim Securities 4th Annual Boston
Healthcare Conference |
|
|
|
|
|
Date: |
|
|
Tuesday, December 13, 2016 |
|
|
|
|
|
Participant: |
|
|
John McDermott, Chief Executive Officer |
About Endologix, Inc.Endologix,
Inc., develops and manufactures minimally invasive treatments for
aortic disorders. The Company's focus is endovascular stent grafts
for the treatment of abdominal aortic aneurysms (AAA). AAA is a
weakening of the wall of the aorta, the largest artery in the body,
resulting in a balloon-like enlargement. Once AAA develops, it
continues to enlarge and, if left untreated, becomes increasingly
susceptible to rupture. The overall patient mortality rate for
ruptured AAA is approximately 80%, making it a leading cause of
death in the United States. Additional information can be found on
Endologix's website at www.endologix.com.
COMPANY CONTACT:
Endologix, Inc.
John McDermott, CEO
Vaseem Mahboob, CFO
(949) 595-7200
www.endologix.com
INVESTOR CONTACTS:
The Ruth Group
Nick Laudico (646) 536-7030
Zack Kubow (646) 536-7020
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Apr 2024 to May 2024
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Endologix Inc (NASDAQ): 0 recent articles
More News Articles